GO
Loading...

Trader Talk with Bob Pisani

More

  Wednesday, 23 Apr 2008 | 3:34 PM ET

Glaxo Buying Sirtris -- A Euro/Dollar Story

Posted By: Bob Pisani

GlaxoSmithKline is paying big in an effort to find cures for diseases of aging. They are buying Sirtris Pharmaceuticals for $720 million in cash, or $22.50/share. This price represents an 84% premium over SIRT's closing price yesterday.

Two things are going on here:

1) this is important, cutting-edge science; Sirtris is the leading research firm seeking to cure diseases of aging by targeting the enzymes that control the aging process, and

2) big pharmaceutical companies are desperate for new drugs and novel technologies; expect more European pharma companies to sniff around and buy U.S. biotechs with their inflated euros.

But it is the potentially revolutionary science that's important here. How can we live longer and healthier? Obviously we can try to cure selective diseases, and maybe find ways of replacing worn-out body parts.

But it has been noted for a while that one of the only treatments that has been demonstrated to extend life appears to be caloric restriction. Read: starvation diet. We're talking 30 percent less than a normal human consumes. This apparently works in rats and yeast, but definitive proof that it radically extends human life is still lacking.

Might there be a way to get the effects of longer, healthier life without the pain of starving yourself? Possibly, and that is where Sirtris comes in.

Sirtris is the leading company develop a drug pipeline based on chemical compounds known as sirtuins. These sirtuins are evidently turned on by a caloric-restricted diet. Small molecules called resveratrol (a chemical substance found in wine) apparently activate these sirtuins and have extended the lifespan of yeast, worms and fruit flies, as well as mice eating a high-calorie diet. In other words, resveratrol increases the activity of the gene associated with sirtuins in the same way that caloric restriction does.

Does this work in humans? We don't know, yet.

Seven sirtuins have been identified that may impact metabolic disorders, cardiovascular diseases and cancer. Sirtris has filed more than 100 patent applications around these sirtuins.

The company's lead drug is called SRT501; it is an enhanced formulation of resveratrol and is currently being tested as a treatment for type II diabetes and MELAS, a rare form of dementia. There are indications that they reduce weight gain, improve glucose levels, and insulin sensitivity.

Sirtris is also developing new chemical entities (NCEs) that are much more potent than SRT501 and should enter clinical testing soon.

I will be interviewing Sirtris' CEO, Christoph Westphal, at 3:20pm ET on Closing Bell.


Questions? Comments? tradertalk@cnbc.com

»Read more
  Wednesday, 23 Apr 2008 | 10:53 AM ET

Bargain Basements: Countrywide Sells Home for $1

Posted By: Bob Pisani

Psst, looking for a cheap place to live? Just how cheap can you buy a home for in some of America's biggest cities?

Check out Countrywide's website of homes they have for sale: http://www.countrywide.com/purchase/f_reo.asp

On that site, you can find homes as low as:

--$1 in Detroit (!)

--$950 in Cleveland

--$1,200 in Buffalo, N.Y.

--$1,900 in St. Louis

--$5,900 in Pittsburgh

--$7,900 in Dallas

--$9,900 in Chicago

--$9,900 in Jacksonville, Fla.

--$24,900 in Denver

--$28,900 in Worcester, Mass.

--$39,900 in Sacramento

--$53,900 in Las Vegas


Questions? Comments? tradertalk@cnbc.com

»Read more
  Wednesday, 23 Apr 2008 | 9:35 AM ET

Boeing's Nice Earnings vs. Weak Water IPO

Posted By: Bob Pisani

Futures about flat as oil is at least down a bit this morning. Earnings were mixed, and an IPO pricing was a bit disappointing.

Boeing earnings better than expected: $1.62 vs. $1.35 est. Reaffirmed 2008 guidance of $5.70-$5.85. For 2009, guidance of $6.80-$7.00 is about in line with expectations.

Ryder handily beat earnings estimates, and raised full year forecast to $4.55-4.75.

How much money can an airline lose? Delta lost $6.4 billion, or $16.15 a share. Its merger partner Northwest reported a net loss of $4.1 billion, or $15.78 a share.

What happened to American Water Works? The IPO price talk was 64 million shares at $24-$26; it priced 58 million at $21.50. This IPO had been postponed before, in November, as the company cited unfavorable market conditions.

Water is certainly a hot space right now. I have heard that valuation was the concern (i.e., it was priced too high). Also heard that retail street allocation was large -- which means institutions did not load up).

Eaton priced 17.5 m shares at $84 a share, which will be used to pay off prior aquisitions. They also affirmed their full year operating earnings.

GlaxoSmithKline is paying big for anti-aging research. They are buying Sirtris Pharmaceuticals for $720 million in cash, or $22.50 per share.

This price represents an 84 percent premium over SIRT's closing price yesterday.
Two things are going on here:
1) this company is the leading research outfit in anti-aging research through very promising chemical compounds (sirtuins) that appear to slow the aging process (they are initially being tested for diabetes), and
2) big pharmaceutical companies are desperate for new drugs and novel technologies; expect more European pharma companies to sniff around and buy U.S. biotechs with their inflated Euros.

I will have the founder and CEO of Sirtris, Christoph Westphal, on Closing Bell at 3:20pm ET.


Questions? Comments? tradertalk@cnbc.com

»Read more
  Tuesday, 22 Apr 2008 | 3:59 PM ET

Two Builders Report Wednesday; Expect Little

Posted By: Bob Pisani

Homebuilders Ryland and Pulte are reporting tomorrow. Don't expect much. There will continue to be significant pricing pressure & writedowns.

Here's the key for the homebuilders. They need to:

-reduce inventory to generate cash

-raise capital

Capital raising is likely, because they are not generating enough cash flow to fund their public debt that is coming due.

Expect more builders to default on their loans, so banks will own more real estate assets, which they will sell at a deep discount.

Already, builders with February quarter ends -- KB Home and Lennar -- reported dramatic declines in sales. At UBS, they are expecting new home prices to decline an additional 10-15%, or ~35% cumulatively in the hottest housing markets.


Questions? Comments? tradertalk@cnbc.com

»Read more
  Tuesday, 22 Apr 2008 | 12:21 PM ET

Soaring Oil a Drag on Markets

Posted By: Bob Pisani

Stocks dropped mid-morning as oil is spiking just shy of $120 . At this point, oil is a major drag on the markets.

Speaking of stocks: we are about one-third through with first-quarter earnings, and it is not shaping up to be a great start.

So far, 143 companies are reporting, 62 percent beat estimates (about in line with historic average), 15 percent matched, 24 percent miss -- which is higher than normal.

But that doesn't really tell the real story.

So far, if you take all 143 companies together, on average companies are missing their estimates by 2.3 percent, thanks to high profile misses by General Electric , Wachovia , Bank of America , Pfizer and others.

Typically, companies as a whole BEAT by about 3 percent. True, a good part of this problem comes from financials, but still it is a stunning reversal of a pattern that has prevailed for many years.

Surprisingly, we are not seeing analysts taking down estimates aggressively for the second quarter.

I say surprisingly, because analysts have been spectacularly wrong going into the last two quarters, forced to aggressively move numbers down. They are not doing it, so far, for the second quarter. They are making modest moves to take financials earnings estimates down, and even more modest moves to take consumer discretionary (retailers) companies down as well (from 0 percent gain to down 2 percent). Is that enough? We'll see.


Questions? Comments? tradertalk@cnbc.com

»Read more
  Tuesday, 22 Apr 2008 | 9:15 AM ET

Pisani: Hot Fertilizer

Posted By: Bob Pisani

Who said the IPO market was dead? Not if you have a hot product. Intrepid Potash (IPI) priced 30 million shares at $32 last night, and will be ringing the opening bell this morning. Was demand strong? You tell me: initial price talk was 24 million shares between $24-$26, then bumped up to 30 million shares between $27-$29, then finally priced at $32.

What's going on? You have a product -- potash -- a critical ingredient in fertilizer. Food supplies are getting scarcer, and fertilizer is one of the best ways to increase yield. So you have international demand, and somewhat constrained capacity. You can also thank demand for ethanol from corn and the need to increase yield there. (Read more about Intrepid here ).

It's amazing it took this long for another major fertilizer company to come along. Look at CF Industries -- they went public in 2005 at $16. Closed yesterday at $156.

We'll be discussing the state of the IPO market this morning at 10:50 ET on Squawk on the Street.

Elsewhere:

1) Southeast bank SunTrust missed earnings by a wide margin ($0.81 vs. $1.03 estimates). The usual suspects -- losses in real estate -- were cited, which is no surprise--they have lots of southeast real estate exposure. There was a spike in problem loans, again associated with residential construction, home equity and residential mortgages.

Traders tell me that management seems optimistic on the conference call, saying things will be better in two quarters. Much of this now depends on your view of the real estate situation in the southeast.

Down 4 percent pre-open.

2) Oppenheimer's Meredith Whitney was right--she said yesterday Citigroup would need to raise more capital, and they did--right after the bell yesterday announced an offering of $6 billion in preferred shares. Carries a dividend of 8.4 percent for 10 years and a floating rate after that. That makes roughly $36 b in capital raising Citi has done since November.

This comes after JP Morgan also raised $6 billion last week.

Speaking of capital raising--CIT raised $1 billion, half in common stock, the other half in convertible preferreds.

3) Dupont beat estimates and reaffirmed their full year guidance . It's important to realize that Dupont now gets about 25 percent of its sales from its Agricultural & Nutrition division, which includes genetically modified seed. Of course, they are most famous for their Performance Materials (polymers, about 25 percent of sales), automotive finishings and coatings (about 20 percent of sales), and safety materials like Tyvek, Kevlar, and Corian (also about 20 percent of sales.

4) McDonald's beat estimates handily, $0.81 vs. $0.70. International sales again were strong: Europe up 11.1 percent in constant currency, Asia/Pacific Middle East and Africa up 16 percent in constant currency, U.S. up 2.9 percent. Menu items, expanded hours, and the dollar all were positive factors.

A few other consumer discretionary stocks beat--Coach and Brinker. Coach reported earnings for their third quarter, affirmed guidance for the rest of the year (one quarter remaining), but declined to give guidance after that.

5) UnitedHealth Group continued the trend of earnings warnings from HMOs; they reduced 2008 guidance by 10 percent, citing unusually high influenza costs, as well as declining membership gains because prices have gone up. Down 10 percent pre-open.


Questions? Comments? tradertalk@cnbc.com

»Read more
  Monday, 21 Apr 2008 | 4:52 PM ET

Texas Instruments Numbers Coulda Been Worse

Posted By: Bob Pisani

Texas Instruments just reported earnings in line. Guidance for the second quarter is weak, 42-48 cents per share, estimate is 48 cents. Down about 2 percent after the close.

For today's trading, it could have been worse.

Particularly in financials, what with National City announcing a $7 billion capital raising, Bank of America disappointing, and Oppenheimer's Meredity Whitney continuing to be sour on Citigroup and Wells Fargo.

On top of that, record oil prices meant energy stocks at new highs , and airline stocks hit new lows, mergers or no.

Not to be outdone, coal stocks hit new highs as Arch Coal raised its guidance and predicted higher coal prices.

Tech outperformance continues: Microsoft , Hewlett have been big helps to the Dow recently.


Questions? Comments? tradertalk@cnbc.com

»Read more
  Monday, 21 Apr 2008 | 12:12 PM ET

April: The Cruelest Month Yet For S&P Or A Turnaround?

Posted By: Bob Pisani

Will April break the losing streak? The S&P is up 5 percent so far in April; but look what it's done the prior five months:

Nov. down 4.4%
Dec. down 0.9%
Jan. down 6.1%
Feb. down 3.5%
Mar. down 0.6%

The S&P has not seen six down months since 1981. Hold your breath.

Elsewhere:

Meredith Whitney at Oppenheimer is having none of this "it could have been worse" theory on big banks. She's still bearish. On Citigroup today she:

--Lowers ests.
--Says they are under pressure to cut/eliminate dividend.
--Says they will likely seek additional capital.

She also downgraded Wells Fargo, saying they are under-reserved for future losses.

My two cents on Bank of America ,which missed this morning : the bad news is asset quality continues to deteriorate, with nonperforming assets increasing in residential mortgages, home equity loans, commercial real estate. The good news is that they are building up their loan reserves in a very responsible manner, one reason the stock is only down 1.6 percent today.


Questions? Comments? tradertalk@cnbc.com

»Read more
  Monday, 21 Apr 2008 | 9:37 AM ET

Bank Of America Continues Monday Woes

Posted By: Bob Pisani

Monday has not been a great day for bank earnings. Last Monday it was Wachovia that disappointed, today futures dropped at 7 am ET as Bank of Americacame short of expectations.

Considerably short: $0.23 vs. expectations of $0.41. Still, we are once again in the "it could have been worse" mode which proved to be a successful argument for Merrill Lynch and Citigroup .

B of A is more heavily exposed to the domestic economy than some of its competitors. They have by far the largest retail banking operations; they get about half of their revenues from loans and leases. Credit card income is about 10 percent of their revenues. So a lot are looking to them for comments on the state of the consumer.

They didn't say much, but the numbers could have been worse.

The bad news: about $2 b in writedowns for CDOs and leverage loans. The good news: some analysts, including UBS , were expecting much worse: $2-$4 b of losses.

Bad news: credit card losses rose, but (good news!) they were not as bad as some feared.

Surprisingly, they are still making plenty of loans, and deposit growth is strong (as it is at many banks).

More good news: no dividend cuts, no capital raising announcements. Bottom line: it could have been worse. Stock about unchanged.

Elsewhere:

1) Pharmaceutical companies are continuing to report comparatively poor earnings, on the heels of Pfizer's poor showing last week.

Merckbeat on bottom line , but revenue fell short of expectations, though they did affirm their full year outlook.

Controversial cholesterol lowering drugs Vytorin and Zetia showed significantly slower sales growth. Merck reiterated the full-year guidance they gave earlier in the year. Up 2 percent pre-open.

Lilly fell short of expectations . Sales of antidepressant drug Cymbalta were strong, as was Ciallis sales. But other drugs, including Zyprexa, were lower than expected. Down 2 percent.

2) Halliburton was in line with expectations. International profits were strong (Q1 revenue was up 24 percent outside of North America), and it was somewhat surprising to see North America up 11 percent as well. Up about 1 percent pre-open.

3) National City getting set for $6 b capital infusion from Corsair Capital, according to the Journal. Down 8 percent.

4) Mattel missed, reporting poor growth in the U.S.,somewhat offset by modest growth overseas.


Questions? Comments? tradertalk@cnbc.com

»Read more
  Friday, 18 Apr 2008 | 4:49 PM ET

Weak Start Ended Being A Strong Week

Posted By: Bob Pisani

The week started out poorly, with Wachovia Bank disappointing, and creating fears that the financials would simply fall apart. It didn't happen; Merrill Lynch and Citi reported big writedowns and poor earnings; but they were not dramatically worse than expected, and those stocks rose, along with most other financials.

Outside of that, earnings were good, with strong tech reports from IBM, Intel, Google, and AMD. Industrials like Caterpillar, United Technologies, and Honeywell were also strong.

»Read more

About Trader Talk with Bob Pisani

  • Direct from the floor of the NYSE, Trader Talk with Bob Pisani provides a dynamic look at the reasons for the day’s actions on Wall Street. If you want to go beyond the latest numbers— Bob will tell you why the market does what it does and what it means for the next day’s trading.

 

  • A CNBC reporter since 1990, Bob Pisani covers Wall Street from the floor of the New York Stock Exchange.

Wall Street